Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children.

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to identify markers to prove rapid improvement of lung function, airway inflammation and bronchodilator response after 2-week LTRA administration.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CHA University
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• children diagnosed with mild persistent asthma patients based on the GINA guidelines

• children old enough to cooperate in performing pulmonary function testing

• legal guardians who sufficiently listen to the purpose and voluntarily agree with the participation to sign a written consent approved by IRB

• children with no respiratory symptoms 4 weeks prior to the beginning of the study

• children without chronic respiratory symptoms.

Exclusion Criteria:

• presence of acute or chronic upper respiratory infections, anatomical nasal disorders (ex, nasal polyps, septum deviation, etc.), previous or current specific immunotherapy.

• use of systemic corticosteroids in past 4 weeks.

• admission or visit of the emergency department in past 4 weeks.